Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|May 22, 2019
Early HER2+ Breast Cancer
Early HER2+ Breast Cancer
Advertisement
Case: A 52-Year-Old Woman withHER2+ Breast Cancer
H & P
- A 52-year-old, postmenopausal woman presented with a mass in her left breast at her annual gynecologic exam; was referred to oncology
- 2 children, menopause at age 49
- No history of cardiovascular disease, no family history of breast cancer
- PE: reveals a slightly overweight woman (BMI = 26 kg/m2), with palpable masses in left breast and left axillary nodes
Imaging
- Mammogram reveals 2.5-cm tumor in left breast
- CT: confirms tumor in left breast and left axillary node involvement (2.6-mm metastasis in 1 node)
Biopsy and labs:
- Histology: invasive ductal adenocarcinoma
- Histologic grade: G2
- ER (-)/ PR (-)
- HER2IHC, 3+
- BRCA1/2status: unknown
Treatment
- She received neoadjuvant TCH-P (docetaxel + carboplatin + trastuzumab + pertuzumab) and achieved pathologic complete response
- Developed grade 3 diarrhea during second cycle of chemotherapy, which required a one-level dose reduction of paclitaxel
- Diarrhea resolved to grade 1/2
- Underwent breast-conserving surgery and removal of left axillary lymph nodes; no residual disease
- Currently completing adjuvant therapy; trastuzumab + pertuzumab (total 18 cycles)
Advertisement
Related to this article
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5